Atrial natriuretic factor during atrial fibrillation and supraventricular tachycardia  by Roy, Denis et al.
JACC Vol. 9. No.3
March 1987:509-14
Atrial Natriuretic Factor During Atrial Fibrillation and
Supraventricular Tachycardia
DENIS ROY, MD, FACC, FRAN<;OIS PAILLARD, MD, DENNIS CASSIDY, MD,
MARTIAL G. BOURASSA, MD, FACC, JOLANTA GUTKOWSKA, PHD,
JACQUES GENEST, OC, MD, MARC CANTIN, MD, PHD
Montreal. Quebec. Canada
509
Plasma immunoreactive atrial natriuretic factor was
measured in 10 patients with chronic atrial fibrillation
before and after cardioversion to sinus rhythm, and in
14 patients during electrophysiologic evaluation of par-
oxysmal supraventricular tachycardia. The mean plasma
concentration of atrial natriuretic factor in atrial fibril-
lation was 138 ± 48 pg/ml and decreased to 116 ± 45
pg/ml 1 hour after cardioversion to sinus rhythm (p <
0.005). The mean plasma concentration of atrial natri-
uretic factor increased from 117 ± 53 pg/ml in sinus
rhythm to 251 ± 137 pg/ml during laboratory-induced
supraventricular tachycardia (p < 0.005). Right atrial
pressures were recorded in 12 patients; the baselineatrial
Peptides with potent vasodilator and diuretic activities have
been purified from animal and human atrial extracts (1-8).
Recently, a direct radioimmunoassay was developed for
measuring atrial natriuretic factor in human plasma (9).
Several reports (10-14) have shown that the release of atrial
natriuretic factor is stimulated by volume sodium loading
and that high concentrations of this hormone are found in
patients with congestive heart failure. However. the stimuli
that induce the release of atrial natriuretic factor remain to
be characterized (15). Furthermore, the role of this hormone
in certain pathophysiologicstates is not well understoodand,
more specifically, little of the previous work in this field
has been conducted in patients with supraventricular tachy-
arrhythmias (12,16-19).
The purpose of this study was to measure changes in
plasma immunoreactive atrial natriuretic factor in two groups:
I) patients undergoing cardioversion of chronic atrial fi-
brillation. and 2) patients undergoing electrophysiologic
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pressure was 4.3 ± 1.9 mm Hg and increased to 7.4 ±
3.6 mm Hg during supraventricular tachycardia (p <
0.005). A modest but significant linear relation was noted
between the changes in plasma atrial natriuretic factor
and right atrial pressure measurements during induced
supraventricular tachycardia (r = 0.60, p < 0.05).
In conclusion, changes in atrial rhythm and pressure
may be an important factor modulating the release of
atrial natriuretic factor in the circulation and raised
levels of this hormone may be a contributing factor for
the polyuria and the hypotension associated with par-
oxysmal supraventricular tachyarrhythmias.
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testing for the assessment of paroxysmal supraventricular
tachycardia. In addition, because the changes in plasma
atrial natriuretic factor activity that occur with these ar-
rhythmias might result from variations in atrial hemody-
namics, we measured the right atrial pressure during lab-
oratory-induced supraventricular tachycardia.
Methods
Study patients. Atrialfibrillation (Table 1). Ten patients
(six men, four women), 48 to 73 years old (mean 60 ±
8), undergoing elective cardioversion for atrial fibrilla-
tion were studied. Three patients had pure mitral stenosis,
one had both mitral regurgitation and stenosis and one had
mitral valve prolapse. Three patients had mild hypertension
with a diastolic pressureof 90 mm Hg or less while receiving
diuretic agents. The remaining two patients had no evidence
of cardiovascular disease by history. physical examination
or M-mode and two-dimensional echocardiography. All pa-
tients were studied on a stable regimen of digitalis and oral
anticoagulants.
Recurrent supraventricular tachycardia (Table 2). This
group consisted of 14 patients (five women, nine men) re-
ferred for electrophysiologic evaluation of recurrent par-
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Tab le 1. Characteristics of the 10 Patients Undergoing Cardioversion For Atrial Fibrillation
AF
Heart Rate
Patient Age (yr) Heart Duration LA (beats/m in) ANF (pg/rnl)
No. &Sex Disease (weeks) (mm) AF SR AF SR (I h) SR (24 h)
48M MS 10 55 100 75 192.2 167.9
2 61M SH > 15 50 90 70 48.3 32.1 50.9
3 59F MS > 10 42 92 72 125.9 123.9 100.6
4 72M SH > 12 47 140 74 206.11 151.4 148.1
5 61M SH.MVP > 15 35 100 68 167.6 121.8 94.2
6 73F SH 2 36 70 68 126.1 89.3
7 55M None > 15 39 90 72 82.3 61.6 48.9
8 51M MS > 18 52 75 70 \57.8 160.7
9 55F None » rs 40 70 70 123.2 Il iA 13 1.3
10 70F MS+MR 12 47 90 75 150.7 144.2 136.5
AF atrial fibrillation; ANF = atrial natriuretic factor; F female; LA = left atrial size by echocardiography; M = male; MR = mitral
regurgitation; MS = mitral stenosis; MVP = mitral valve prolapse; SH = systemic hypertension; SR = sinus rhythm; - = data nat available.
oxysmal supraventricular tachycardia. Their ages ranged
from 15 to 64 years (mean 39 ± 18) . One patient had
idiopathic cardiomyopathy and one patient had coronary
artery disease. Twelve patients were without clinical evi-
dence of heart disease.
Of the 24 patients studied, none had congestive heart
failure or renal failure. The blood urea nitrogen, serum
creatinine and serumelectrolytes were normal inall patients.
Procedures. Cardioversion. The subjects with atrial fi-
brillation underwent direct current cardioversion while in
the fasting state after receiving a short-acting barbiturate.
Synchronizedshocks of 150to 300J successfully terminated
the arrhythmias in all instances. All pre- and postcardio-
version blood samples for atrial natriuretic factor measure-
ment were drawn from a forearm vein with the subject in
the supine rest position for 15 to 30 minutes.
Electrophysiologic evaluation . The 14 patients with a
history of recurrent supraventricular tachycardia were eval-
uated for clinical purposes in the cardiac electrophysiology
laboratory while in the postabsorptive state and while re-
ceiving no medication for at least 72 hours. Each patient
gave written informed consent. Four quadripolar catheters
(for sensing and pacing) were inserted percutaneously using
lidocaine local anesthesia through the femoral veins or left
basilic vein and placed in the right atrium. right ventricle.
coronary sinus and across the tricuspid valve for His
bundle recording. A USCI 5520 No.6 catheter with the tip
in the right atrium was used for measurement of the right
Tab le 2. Characteristics of the 14 Pat ient s With Supraventric ular Tachycardia
Right Atrial
Heart Rate Pressure (rnm Hg) ANF (pg/ml)
Patient Age (yr) Heart (beats/min) Past-SVT Post-SVT
No. & Sex Disease SVT SR SVT SR SVT (15 min) SR SVT (15 min)
20M None AP 70 220 5.5 7 6 119 193.7
2 42M CM AP 65 150 6 )() 5 125.7 226.5 112.4
3 63F None AVN 70 160 4 8 4 228. 1 290.3 99.7
4 33M None AP 72 205 3 14 7.5 83.6 228.7 116.2
5 25F None AP 60 200 I 7 I 79.2 333.5 94.4
6 24F None AVN 100 200 2 3 I 207.9 222.5 \67 .1
7 17F None AP 60 155 2 3.5 1.5 140.4 552.4 282.6
8 35M None AP 75 1115 5 6.5 I 62. 1 89.9
9 64M CAD AVN 55 160 4 2 2 106.7 1211 .8
)() 15M None AP 60 160 6 7 6.5 59.9 94.4 49.4
I I 63M None AVN 50 155 91.4 174.7 79.7
12 32M None AP 75 200 6 12 7 6 1.11 142.1
13 58M None AP 70 195 172.4 448.4 156.2
14 54F None AP 60 160 6.5 9 5 102.8 385.9
AP = accessory pathway; AVN = atrioventricular nodal reentry; CAD = caronary artery disease; CM = cardiomyopathy; SVT = supraventricular
tachycardia; other abbreviations as in Table I .
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Figure I . Levels of plasma immunoreactive atrial natriuretic fac -
tor IANF) in 10 patients during atrial tibrillation (A .F.) and I and
24 hours afte r (pOST) cardioversion to sinusrhythm . Dottedlines,
values for individual patients: solid line, mean values for thegroup
as a whole .
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version to sinus rhythm (p < 0.005). The change was small
and nonsignificant between the I hour (107 ± 44 pg/ml)
and the 24 hour measurements (102 ± 40 pg/ml). There
was no significant correlation between the heart rate and the
plasma atrial natriuretic factor concentration either during
atrial fibrillation (r = 0.51) or during sinus rhythm (r =
0.55). There was no significant difference in systolic and
diastolic arterial pressures before and after cardioversion
( 121 :!:: 14/77 ± II versus 11 9 ± 13/77 ± 5 mrn Hg).
Supraventr icular tachycardia (Fig. 2 to 4). The mean
plasma concentration of atrial natriuretic factor increased
from 117 :!:: 53 pg/ml at rest to 251 ± 137 pg/ml during
supraventricular tachycardia (p < 0.(05) and decreased to
125 ± 69 pg/ml 24 hours after the study (p < 0.0005).
The mean right atrial pressure (Fig. 3) was 4.3 ± 1.9
0101 Hg during sinus rhythm and increased during supra-
ventricular tachycardia to 7.4 ± 3.6 0101 Hg (p < 0.005).
Within 15 minutes after terminating the tachycardia. right
atrial pressure decreased to 4 ± 2.5 0101 Hg (p < 0.0(05).
Only one patient demonstrated a decrease in right atrial
pressure during tachycardia that was associated with a slight
increase in atrial natriuretic factor production (Fig. 4). In
all other instances. the plasma atrial natriuretic factor levels
and right atrial pressures increased during the tachycardia .
Results
Atrial fibrillation (Fig. I). The mean plasma concen-
tration of atrial natriuretic factor in the 10 patients with
chronic atrial fibrillation decreased from 138 :!:: 48 pg/rnl
before cardioversion to 116 ± 45 pg/ml I hour after con-
atrial pressure. The intracardiac electrograms were filtered
at 30 to 500 Hz and simultaneously displayed with three
surface electrocardiographic leads ( I. aVF. VI) on a mul-
tichannel oscilloscope (Electronics for Medicine VR 12).
In addition, all data were recorded with an ink-jet recorder
(Elcrna Mingograph) at paper speeds of 25 to 250 mm/s and
stored on magnetic tape. The atrial pressure was processed
through a Bentley 800 transducer and model V2206A am-
plifier in the Electronics for Medicine recorder.
In each patient , baseline e1ectrophysiologic intervals, ar-
terial blood pressure, right atrial pressure and right atrial
blood samples for atrial natriuretic factor were obtained
during sinus rhythm. Supraventricular tachycardia was then
induced with a programmable stimulator using a stimulation
protocol that included atrial and ventricular incremental pac-
ing at cycle lengths of 500 to 250 ms for 10 to 30 seconds
and cxtrastimulus testing during two paced cycle lengths
(600 and 400 ms). The measurements obtained at baseline
were repeated 5 minutes after the first induced stable supra-
ventricular tachycardia and subsequently repeated at the end
of the electrophysiologic procedure. Blood samples for atrial
natriuretic factor were also drawn 24 hours later from a
forearm vein with the subject in the supine position and
experiencing sinus rhythm.
Measurements of atrial natriuretic factor. Blood sam-
ples for atrial natriuretic factor were taken into cold tubes
containing ethylenediaminetetraacetic acid and (per I rnl
blood) pepstatin, 10 p.1 (500 p.M), and PMSF. 10 p.1 (10'
M ). Blood was centrifuged at 4,000 rpm for 20 minutes at
4°C. Plasma was stored at - 70°C for 2 to 4 days and
immunoreactive atrial natriuretic factor was measured by
radioimmunoassay (9). The sensitivity of the method is
1.9 pg/ml.
Statistical analysis. The data were assessed by Student' s
t test for paired and unpaired data. The strength of asso-
ciation between the changes in plasma concentration of im-
munoreactive atrial natriuretic factor and right atrial pressure
was assessed by linear regression analysis using the plasma
atrial natriuretic factor ratio (plasma level during tachycardia
divided by baseline plasma level during sinus rhythm) and
the right atrial pressure ratio (right atrial pressure during
tachycardia divided by baseline right atrial pressure during
sinus rhythm); the coefficient of regression was calculated
by the method of least squares.
All values are expressed as mean ± I SD. A probability
value of < 0.05 was considered indicative of a significant
difference.
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Figure 4. Relation between changes in right atrial (RA) pressures
and plasma atrial natriuretic factor (ANF) levels in II patients
before (PRE) and after induction of supraventricular tachycardia
(SYT).
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Figure 2. Plasma immunoreactive atrial natriuretic factor (ANF)
levels in 14 patients before (PRE) induction of supraventricular
tachycardia (SYT),. during supraventricular tachycardia and 24
hours after (POST) the study. Symbols as in Figure 1.
Figure 3. Changes in right atrial (RA) pressure in 12 patients
before (PRE) induction of supraventricular tachycardia (SYT).
during the tachycardia and 15 minutesafter (POST) its termination.
Symbols as in Figure 1.
PRE SVT SVT POST SVT
When the plasma atrial natriuretic factor ratio was compared
with the right atrial pressure ratio, a modest but significant
(p < 0.05) linearregressionwas noted (regressioncoefficient
r = 0.60).
The mean heart rate during supraventricular tachycardia
was 179 ± 24 beats/min (range 155 to 220). There was no
significant correlation between the heart rate and the atrial
natriuretic factor concentration either during sinus rhythm
(r = 0.43) or during supraventricular tachycardia (r =
0.11). The mean systolic/diastolic arterial pressures were
124 ± 16/79 ± 5 mm Hg during sinus rhythm and 118 ±
16/79 ± 15 during the tachycardia; the decrease was not
significant.
12 12 12
Discussion
There are three main findings in this study. First, the
plasma concentrations of atrial natriuretic factor in patients
with chronic atrial fibrillation decrease after restoration to
sinus rhythm. Second, plasma concentrations of atrial na-
triuretic factor increase markedly and rapidly during labo-
ratory-induced supraventricular tachycardia. Third, the in-
crease in right atrial pressure during supraventricular
tachycardia may be a contributing factor for the release of
atrial natriuretic factor. Taken together, these findings sug-
gest that the release of atrial natriuretic factor in the cir-
cuiation is rapid and is modulated by changes in atrial rhythm
and pressure.
Mechanism of secretion of atrial natriuretic factor
during supraventricular tachyarrhytitmias. The exact
mechanism underlying the secretion of atrial natriuretic fac-
tor has not yet been defined. Immunocytochemical studies
indicate that both atria contain atrial natriuretic factor al-
though more in the cardiocytes of the right than the left
atrium (20). Our results of parallel increase in right atrial
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pressure and plasma atrial natriuretic factor during supra-
ventricular tachycardia are consistent with the view ex-
pressed by others that acute atrial distension elicits the re-
lease of this substance (10,12,15,17,21 ). We did not measure
atrial pressure during atrial fibrillation. However, previous
studies have shown that the mean atrial pressure increases
with the onset of atrial fibrillation and decreases after car-
dioversion to sinus rhythm (22,23). These findings may
indicate that chronic atrial stretch contributed to the high
plasma atrial natriuretic factor levels during atrial fibrilla-
tion.
Effects of release of atrial natriuretic factor during
supraventricular tachyarrhythmias. Our results may be
used to gain insights into some of the pathophysiologic
phenomena associated withparoxysmalatrialfibrillation and
supraventricular tachycardia. Wood first spoke about the
polyuria associated withparoxysmal supraventricular tachy-
arrhythmias in 1961 . His observations were reported in
1963 by Campbell (24) and laterconfirmed by others (25-27).
Infusion of atrial peptides produces potent diuretic and na-
triuretic effects in rats (2-4,6) and humans ( 12,13). Plasma
atrial natriuretic factor levels were measured during par-
oxysmal supraventricular tachyarrhythmias in fi ve prelim-
inary studies with a total of 16 patients (12,16-19). The
rapidity and the magnitude of increase in plasma atrial na-
triuretic factor observed with supraventricular tachycardia
in these studies is in agreement with our find ings and may
explain the polyuria and natriuresis associated with parox-
ysmal supraventricular tachycardia. However. our data sug-
gest that elevated immunoreactive atrial natriuretic factor
levels are not necessarily related to this phenomenon be-
cause high atrial natriuretic factor levels werealso recorded
in patients with chronic atrial fibrillation, which is not as-
sociated with polyuria. It may be that chronically elevated
levels of atrial natriuretic factor lead to a resetting of the
specific renal receptors.
The atrial natriuretic peptides also relax vascular smooth
muscle. oppose the vasoconstrictive effects of angiotensin
and reduce renin and aldosterone secretion (5. 15.28-34).
It has been shown that systolic and diastolic blood pressures
decrease significantly in some patients during a paroxysm
of atrial fibrill ation or supraventricular tachycardia and that
these arrhythmias may produce dizziness and syncope in
patients who are otherwise in good health and without or-
ganic heart disease (24,35). A contributing factor for the
disabling symptoms in these patients may be due to the
hypotensive effects of a marked increase in plasma atrial
natriuretic factor activity.
Conclusions. Changes in atrial pressure and rhythm are
probably involved in inhibiting and inducing cardiac secre-
tion of atrial natriuretic factor. This hormone may play a
role in the polyuria and hypotension sometimes associated
with paroxysmal supraventricular tachyarrhythmias. Fi-
nally. the laboratory induction of reentrant supraventricular
tachycardia providesan experimental model to furtherstudy
the physiologic effects of endogenous atrial natriuretic factor
in humans.
We are indebted to Richard Cartier and Manon Labelle for technical as-
sistance. and to Luce Begin for preparing the manuscript.
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